Drug Interaction Report
2 potential interactions and/or warnings found for the following 2 drugs:
- etravirine
- irinotecan
Interactions between your drugs
irinotecan etravirine
Applies to: irinotecan, etravirine
MONITOR: Coadministration with inducers of the CYP450 3A4 isoenzyme may decrease the plasma concentrations of irinotecan and its pharmacologically active metabolite, SN-38. Irinotecan is partially metabolized by CYP450 3A4, and induction of this process results in less of the drug available in the plasma for conversion to SN-38 via carboxylesterases. The interaction has been reported with St. John's wort and the enzyme-inducing anticonvulsants carbamazepine, phenobarbital, and phenytoin. An approximately 40% reduction in SN-38 systemic exposure (AUC) has been reported in the presence of St. John's wort and greater than 60% reductions have been reported in the presence of enzyme-inducing anticonvulsants. However, all of these agents are known to be potent inducers of CYP450 3A4 as well as other enzymatic pathways (e.g., UDP-glucuronosyl transferase, or UGT; carboxylesterases) and drug transporters (e.g., multispecific organic anion transporter, or MRP2; P-glycoprotein) that may be involved in the clearance of irinotecan and/or SN-38. The extent, if any, to which irinotecan may interact with less potent CYP450 3A4 inducers is unknown.
MANAGEMENT: The antitumour activity of irinotecan may be reduced in patients treated with CYP450 3A4 inducers. Pharmacologic response to irinotecan should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the irinotecan dosage adjusted as necessary.
References (15)
- (2001) "Product Information. Camptosar (irinotecan)." Pharmacia and Upjohn
- De Bruijn P, De Jonge MJ, Mathijssen RH, Sparreboom A, Verweij J (2002) Modulation of irinotecan(CPT-11)metabolism by St. John's wort in cancer patients. http:aacr02.agora.com/planner/displayabstract.asp?presentationid=2603
- Murry DJ, Cherrick I, Salama V, et al. (2002) "Influence of phenytoin on the disposition of irinotecan: a case report." J Pediatr Hematol Oncol, 24, p. 130-3
- Mathijssen RH, Verweij J, De Bruijn P, Loos WJ, Sparreboom A (2002) "Effects of St. John's Wort on Irinotecan Metabolism." J Natl Cancer Inst, 94, p. 1247-9
- Kuhn JG (2002) "Influence of anticonvulsants on the metabolism and elimination of irinotecan. A North American Brain Tumor Consortium preliminary report." Oncology (Williston Park, 16(8 Suppl 7), p. 33-40
- Friedman HS, Petros WP, Friedman AH, et al. (1999) "Irinotecan therapy in adults with recurrent or progressive malignant glioma." J Clin Oncol, 17, p. 1516-25
- Santos A, Zanetta S, Cresteil T, et al. (2000) "Metabolism of irinotecan (CPT-11) by CYP3A4 and CYP3A5 in humans." Clin Cancer Res, 6, p. 2012-20
- Yonemori K, Takeda Y, Toyota E, Kobayashi N, Kudo K (2004) "Potential interactions between irinotecan and rifampin in a patient with small-cell lung cancer." Int J Clin Oncol, 9, p. 206-9
- Innocenti F, Undevia SD, Ramirez J, et al. (2004) "A phase I trial of pharmacologic modulation of irinotecan with cyclosporine and phenobarbital." Clin Pharmacol Ther, 76, p. 490-502
- Di YM, Li CG, Xue CC, Zhou SF (2008) "Clinical drugs that interact with St. John's wort and implication in drug development." Curr Pharm Des, 14, p. 1723-42
- Crews KR, Stewart CF, Jones-Wallace D, et al. (2002) "Altered irinotecan pharmacokinetics in pediatric high-grade glioma patients receiving enzyme-inducing anticonvulsant therapy." Clin Cancer Res, 8, p. 2202-9
- Radomski KM, Gajjar AJ, Kirstein MN, et al. (2000) "Irinotecan clearance is increased by concomitant administration of enzyme inducers in a patient with glioblastoma multiforme." Pharmacotherapy, 20, p. 353
- Minami H, Lad TE, Nicholas MK, Vokes EE, Ratain MJ (1999) "Pharmacokinetics and pharmacodynamics of 9-aminocamptothecin infused over 72 hours in phase II studies." Clin Cancer Res, 5, p. 1325-30
- Zamboni WC, Gajjar AJ, Heideman RL, et al. (1998) "Phenytoin alters the disposition of topotecan and N-desmethyl topotecan in a patient with medulloblastoma." Clin Cancer Res, 4, p. 783-9
- (2015) "Product Information. Onivyde (irinotecan liposomal)." Merrimack Pharmaceuticals
Drug and food interactions
etravirine food
Applies to: etravirine
ADJUST DOSING INTERVAL: Coadministration with food increases the oral bioavailability of etravirine. The mechanism is unknown. Compared to administration following a meal, the systemic exposure (AUC) to etravirine was decreased by about 50% when the drug was administered under fasting conditions. The types of meal studied (ranging from 345 kilocalories containing 17 grams fat to 1160 kilocalories containing 70 grams fat) did not appear to make a difference with respect to impact on etravirine bioavailability.
MANAGEMENT: Etravirine should always be administered following a meal.
References (1)
- (2008) "Product Information. Intelence (etravirine)." Ortho Biotech Inc
Therapeutic duplication warnings
No duplication warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
See also:
Cabenuva
Cabenuva (cabotegravir and rilpivirine) injections are a long-acting HIV treatment used to keep HIV ...
Biktarvy
Biktarvy is a complete HIV-1 treatment in a once-a-day single tablet containing three antiviral ...
Ozempic
Learn about Ozempic (semaglutide) for type 2 diabetes treatment, weight management, cardiovascular ...
Descovy
Descovy is used to treat and prevent HIV infection in adults and adolescents. When used for HIV-1 ...
Dovato
Dovato is a complete HIV-1 treatment regimen in one tablet that may be used in adults and children ...
Truvada
Truvada is used to prevent HIV (HIV PrEP) or treat HIV-1 infection in combination with other HIV-1 ...
Atripla
Atripla prevents the human immunodeficiency virus (HIV) from reproducing in your body. Learn about ...
Isentress
Isentress is used to treat HIV, which causes acquired immunodeficiency syndrome (AIDS). Learn about ...
Viread
Viread (tenofovir) is used to treat HIV, which causes the acquired immunodeficiency syndrome ...
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.